Patent · US Active

Treatment of amyotrophic lateral sclerosis (ALS)

US12116589B2 · kind B2 · utility

0Cited by

281References

20Claims

0Family size

Assignee

VOYAGER THERAPEUTICS, INC. · US

Inventors

Dinah Wen-Yee Sah · Boston, US
Qingmin Chen · Wuxi, CN
Joan R. Coates · Columbia, US
Holger Patzke · Cambridge, US
Jinzhao Hou · Cambridge, US

Key dates

Filing date	Aug 4, 2022
Grant date	Oct 15, 2024
Priority date	—
Expiry date	Aug 4, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2750/14143
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and/or canine degenerative myelopathy (DM).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.